A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Exclusion Criteria

• •Subject who had previous bone marrow transplantation (HSCT) or treatment with ex-vivo gene therapy (eli-Cel).
• •Subject has known type 1 or type 2 diabetes.
• •Subject has known hypersensitivity or intolerance to pioglitazone or any other thiazolidinedione.
• •Subject is taking or has taken honokiol, pioglitazone, or other thiazolidinediones within 3 months prior to Screening.
• •Subject with current participation in another interventional clinical study or within 1 month prior to Screening.
• •Subject with other medical, neuropsychiatric or social conditions that, in the opinion of the investigator, are likely to adversely affect the risk-benefit of study participation, interfere with study compliance, or confound the study results.